Search alternatives:
significant point » significant amount (Expand Search), significant part (Expand Search), significant event (Expand Search)
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
significant point » significant amount (Expand Search), significant part (Expand Search), significant event (Expand Search)
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
-
1
-
2
Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups.
Published 2025Subjects: -
3
-
4
-
5
-
6
-
7
-
8
-
9
Average % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for brown non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.
Published 2024“…<p>Average % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for brown non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.…”
-
10
Average of % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for garbanzo non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.
Published 2024“…<p>Average of % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for garbanzo non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.…”
-
11
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
12
-
13
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
14
-
15
-
16
-
17
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
18
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
19
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
20
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: